Plasma amino‐terminal pro‐brain natriuretic peptide levels in subjects presenting to the Emergency Department with suspected acute coronary syndrome: possible role in selecting patients for follow up?
- 20 May 2001
- journal article
- research article
- Published by Wiley in Internal Medicine Journal
- Vol. 31 (4) , 211-219
- https://doi.org/10.1046/j.1445-5994.2001.00042.x
Abstract
Background: Plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP) level is a sensitive and specific indicator of cardiac dysfunction. Aim: To determine whether plasma NT-proBNP level is elevated at the time of presentation with acute coronary syndrome (ACS) and whether it may assist in the diagnosis of heart failure and myocardial ischaemia in the Emergency Department. Methods: Plasma NT-proBNP levels were measured prospectively in 201 unselected presentations to the Emergency Department with suspected ACS where cardiac injury markers were requested by clinicians as part of routine assessment. NT-proBNP levels were correlated with clinical, electrocardiogram (ECG), biochemical and radiological findings. Results: Elevated NT-proBNP level detected heart failure with high sensitivity (95–96%). Among patients without heart failure, NT-proBNP levels were increased more frequently in patients with previously diagnosed ischaemic heart disease. Elevated NT-proBNP level predicted cardiomegaly and a cardiac cause of presentation. However, the NT-proBNP level was not associated with ECG or biochemical markers of myocardial ischaemia, and only one-third of patients with ACS showed an increase of 40% or more in NT-proBNP level at repeat measurement of cardiac injury markers 5 h after presentation. Conclusions: Although elevated NT-proBNP level detected heart failure with high sensitivity, NT-proBNP level did not assist in the diagnosis of acute myocardial ischaemia. These findings indicate that the major determinant of elevated NT-proBNP level on presentation with suspected ACS was underlying cardiac dysfunction rather than acute myocardial ischaemia. This suggests that NT-proBNP measurement in patients with a suspected cardiac reason for presentation to the Emergency Department may identify a previously unrecognized group of patients without acute ischaemia who may nevertheless benefit from further investigation of cardiac function. (Intern Med J 2001; 31: 211–219)Keywords
This publication has 29 references indexed in Scilit:
- Biochemical detection of left-ventricular systolic dysfunctionThe Lancet, 1998
- Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban populationThe Lancet, 1997
- Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairmentClinical Endocrinology, 1997
- Superiority of Brain Natriuretic Peptide as a Hormonal Marker of Ventricular Systolic and Diastolic Dysfunction and Ventricular HypertrophyHypertension, 1996
- Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment.Heart, 1996
- Acute changes in atrial natriuretic peptide, insulin-like growth factor-1, and lactate levels during left anterior descending coronary artery angioplastyAmerican Heart Journal, 1995
- Transient myocardial ischemia stimulates atrial natriuretic factor releaseAmerican Heart Journal, 1992
- Plasma levels of atrial natriuretic peptide during myocardial ischemia induced by percutaneous transluminal coronary angioplasty or dynamic exerciseAmerican Heart Journal, 1989
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart FailureNew England Journal of Medicine, 1986